Alnylam submits supplemental new drug application (snda) to the u.s. food and drug administration for vutrisiran for the treatment of transthyretin amyloidosis with cardiomyopathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced the submission of its supplemental new drug application (snda) to the u.s. food and drug administration (fda) for vutrisiran, an investigational rnai therapeutic in development for the treatment of attr amyloidosis with cardiomyopathy (attr-cm). vutrisiran is the generic name for amvuttra®, which is currently approved by the u.s. fda for the treatment of the po.
ALNY Ratings Summary
ALNY Quant Ranking